ArticleJournal of registry management2026
Preliminary Estimates of New Invasive Cancers Diagnosed in 2023 in the United States.
Article in Journal of registry management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Incidence of new cancer cases is tracked by population-based cancer registries. Collecting complete information from initial diagnosis through first course of treatment can take up to 2 years. In June 2025, the United States (US) Centers for Disease Control and Prevention (CDC) released reports of cancer incidence for cases diagnosed through 2022, the most recent diagnosis year for which complete cancer incidence data were available. Having more timely data may be useful in planning cancer prevention and control efforts, and preliminary incidence estimates may help fill that gap. Materials and methods: We estimated preliminary rates and counts of new cancer cases in 2023 using reported US Cancer Statistics data for 2000 to 2019 and age-period-cohort models to account for changes in population size, age distribution, and cancer risk. Estimates were calculated for all cancers combined and 23 common cancers by sex (male and female). As a validation of the model, we compared observed and modeled rates for 2022. Results: In 2023, an estimated 1,967,906 new cancer cases were diagnosed in the US, with an age-adjusted preliminary rate of 462 cases per 100,000 standard population. In a validation analysis, observed and modeled rates for 2022 were similar (0.5% percentage difference, on average), indicating that the age-period-cohort models performed well. Conclusion: Cancer registries are currently implementing data modernization strategies to improve timeliness of data. In the interim, preliminary incidence estimates can fill in gaps between cancer occurrence and cancer reporting. These early cancer rates and counts may be useful in guiding research and helping public health care professionals focus on areas of concern for cancer prevention and control efforts.
Indexed as
Identifiers
42267113PMC13245668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.